Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 99   

Articles published

SLXP 102.34 -0.57 (-0.55%)
price chart
Why Salix Pharmaceuticals Ltd. Stock Was Throttled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Salix Pharma says inventory rises, cuts 2014 forecast  Reuters
Salix Audit Committee to Review Inventory as CFO Resigns  Bloomberg
Related articles »  
Deadline in Lawsuit for Investors in Salix Pharmaceuticals, Ltd. (SLXP) Shares ...
Furthermore, the plaintiff alleges that Salix Pharmaceuticals, Ltd's reserves for outstanding inventory were understated and, because of this understatement, its reported quarterly and annual net revenue and earnings per share figures were overstated ...
Latest Updates on Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)  Inside Trade
Related articles »  
Salix Pharmaceuticals Announces Plan to Augment Board of Directors
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (�Salix� or the �Company�) today announced that it has engaged Russell Reynolds Associates, a nationally recognized search firm, to conduct a comprehensive search to ...
Related articles »  
Stock in Focus: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
[BUSINESS WIRE] Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP) (Trend Analysis) announced that Dr. Anthony Lembo of Beth Israel Deaconess Medical Center will present the results of TARGET 3 in a late-breaking podium presentation at the American ...
How Adam Feuerstein Follows The Biotech Sector
Anyone who trades or invests in biotech stocks knows how volatile they can be, according to Adam Feuerstein. Feuerstein is a senior columnist for TheStreet.
Related articles »  
Salix Q3 Earnings Preview: Revenue Growth On A Decline
Salix Pharmaceuticals, Ltd. (SLXP) is expected to report its financial and operational results for the third quarter of 2014 fiscal year (3QFY14) after the markets close tomorrow.
Midday Losers From November 7: Roka Bioscience, Salix Pharmaceuticals ...
Roka Bioscience Inc (NASDAQ: ROKA) -52%; The company announced downbeat third quarter results Thursday; Bank of America downgraded the stock.
Related articles »  
Credit Suisse Boosts Salix Pharmaceuticals Price Target to $111.00 (SLXP)
Salix Pharmaceuticals, Ltd. logo Salix Pharmaceuticals (NASDAQ:SLXP) had its target price boosted by Credit Suisse from $85.00 to $111.00 in a report issued on Friday.
SHAREHOLDER ALERT: Investors of Salix Pharmaceuticals, Ltd. with Losses of ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the �Class�) comprising purchasers of the ...
Related articles »  
EyeCatching Stocks - First Niagara Financial Group Inc.(NASDAQ:FNFG), Salix ...
Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP) declared that it has engaged Russell Reynolds Associates, a nationally recognized search firm, to carry out a comprehensive search to assist the Company in identifying experienced, highly qualified individuals ...
Related articles »